Effects of tiflucarbine as a dual protein kinase C/calmodulin antagonist on proliferation of human keratinocytes and release of reactive oxygen species from human leukocytes
✍ Scribed by L. Hegemann; R. Fruchtmann; B. Bonnekoh; B. H. Schmidt; J. Traber; G. Mahrle; R. Müller-Peddinghaus; L. A. A. Rooijen
- Book ID
- 104745605
- Publisher
- Springer-Verlag
- Year
- 1991
- Tongue
- English
- Weight
- 591 KB
- Volume
- 283
- Category
- Article
- ISSN
- 0340-3696
No coin nor oath required. For personal study only.
✦ Synopsis
Various studies have suggested that calmodulin (CAM) is involved in the pathophysiology of psoriasis. Protein kinase C (PKC) is also accepted as playing a regulatory role in cell proliferation as well as in inflammatory processes. Therefore, we investigated the effects of the known CaM antagonist tiflucarbine (BAY/TVX P 4495) on two cellular systems related to the major clinical symptoms of psoriasis: proliferation of cultured human keratinocytes (HaCaT cell line) and release of reactive oxygen species (ROS) from human polymorphonuclear leukocytes (PMNL). Tiflucarbine inhibited both cellular responses in a dose dependent manner. Furthermore, tiflucarbine directly affected PKC, and may thus be considered to be a dual PKC[CaM antagonist with putative antipsoriatic activity. The effects of tiflucarbine on the different parameters were compared with those of the structurally unrelated dual PKC/CaM inhibitor W-7 and those of the potent PKC inhibitor staurosporine. The potencies of all three compounds were found to be in the same range as their PKCinhibiting potency. Our data indicate that PKC, rather than CaM, may play a regulatory role in the release of ROS as well as in keratinocyte proliferation. Therefore, inhibition of PKC in general might have a therapeutic benefit in psoriasis.